International Journal of Medicine and Nanotechnology
Access online at www.medtechnano.com

Original Article

Quality of life, fulfillment and clinical efficacy in patients with beta thalassemia major and sickle cell anemia undergoing oral chelation therapy with deferasirox

Dr. Vijaya Kuchana, Pradeep Kumar *, Masrath Anjum*
Teegala Krishna Reddy College of Pharmacy, Meerpet, Hyderabad-500079, India

Article Received on: 11/11/2017 Accepted on: 24/11/2017

ABSTRACT

QOL is the common health of person and group of persons, indicating negative and positive characteristics of life. The target of this individual-center observational trail was to assess the standard of life, clinical efficacy, and fulfillment in pediatric and adult sufferers with Beta Thalassemia and Sickle cell anemia receiving accepting deferasirox (DFX) chelation treatment. An individual center, observational trail was performed among 37 patients with Beta thalassemia or Sickle cell anemia who accepted DFX (20–40 mg/kg/day) ICT from Om Sai Hospital from December 2016 to July 2017 participated. The reason for this single-center observational trail was to assess QOL, clinical efficacy, and satisfaction in sufferers with BTM and SCA accepting DFX chelation treatment to contribute to their therapy and support process. The outcomes of the present trail indicate that the DFX-managed sufferers with BTM or SCA are not achieving their target hematological marker thresholds (mainly serum ferritin levels) despite long-term therapy for iron over burden. In addition, DFX chelation treatment appears to negative impact their HRQOL so that the sufferer's fulfillment with ICT is usually poor. Overall, the patients involved in the study had not achieved target serum ferritin thresholds despite long-term treatment for iron overload with DFX chelation therapy. Observed compliance to DFX was generally poor, and treatment appeared to negatively impact the quality of life and satisfaction of the patients. Our data also suggest that majority of the patients and/or their parents do not know about the importance of their medication.

Key Words: Deferasirox, chelation Therapy, serum ferritin threshold.

www.medtechnano.com
Quick Response code

Corresponding Author
Pradeep Kumar,
Teegala Krishna Reddy College of Pharmacy,
Hyderabad-500079, India
Email.Id: pharmacologypradeep@gmail.com

1. INTRODUCTION

SCA is a congenital disorder[1, 2] of the RBCs. Usually, RBCs are created like discs, which gives them the pliability to move through even the little blood vessels. However, with this disorder, the RBCs contain an atypical crescent form duplicating a sickle. This makes them

viscous and stiff and disposed to getting tricked in small vessels, which stops blood from approaching different organs of the human body. This can cause pain and tissue damage[3,4]

SCD is states of autosomal recessively .we require 2 duplicates of gene to have the disorder. If a person having only 1 duplicate of gene, can be considered as a trait of sickle cell.

Indications of SCA generally show up at a early years of life time. They may occurs in new born babies as soon as four months of age yet usually happens nearby 6-months[4,5,6].

Thalassemia is a blood disease passed through families in which the body prepares an unusual form of Heam. Hemoglobin is the protein in RBCs that supplies oxygen. The disease effects in large numbers of RBCs being demolished, which promotes to anemia[7,8].

Beta thalassemia is a blood disease that decreases the formation of hemoglobin. Hemoglobin is the iron-carrying protein in RBCs that supplies oxygen to cells along the body.

In individuals with beta thalassemia, lower levels of hemoglobin began to a deficiency of oxygen in numerous parts of the body[9,10]. Affected persons also have a deficiency of RBCs, which can produce pale skin, fatigue, weakness and more serious complications. Individuals with β thalassemia are at an elevated threat of producing unusal blood clots. β thalassemia is categorized into 2 types based on the severity of indications: thalassemia major (also known as Cooley's anemia) and thalassemia intermedia. Of the 2 types, thalassemia major is more serious.

The target of this individual-center observational trail was to assess the standard of life, clinical efficacy, and fulfillment in pediatric and adult sufferers with Beta Thalassemia and Sickle cell anemia[11, 12, 13] receiving deferasirox (DFX) chelation treatment. To measure Perceived effectiveness. To measure acceptance/approval. To measure burden of ICT. To measure side effects.

2. EXPERIMENTAL SECTION

An individual center, observational trail was performed among 18 patients with Beta thalassemia or Sickle cell anemia who accepted DFX (20–40 mg/kg/day) ICT from Om sai Hospital from December 2016 to July 2017 participated. The protocol of this study was approved by Clinical Research Ethics Committee of INDIA.

INCLUSION AND EXCLUSION CRITERIA

Participants were selected depending on the following criteria's.

Inclusion criteria are

(1) Patients willing to participate in the study,

(2) Patients diagnosed with Beta thalassemia or Sickle cell anemia, and

(3) Patients who are accepting DEFERASIROX for minimum of six months duration.

Exclusion criteria were

(1) Patients who are not matching for the inclusion criteria's,

(2) Patients not ready to participate in the study,

(3) Patients recognized with other types of anemia,

(4) Patients who are not accepting DEFERASIROX for minimum of 6 months, and

(5) Patients having other states such as physical and/or mental problems which may trouble sufferers

STUDY INSTRUMENTS AND DATA COLLECTION

At the beginning of the study, all eligible patients and/or their parents were informed of the objectives of the study and confident that all data would stay personal. After receiving written informed consent with sigh from the sufferer and/or their sufferer's attendants, the following data were obtained:

(1) Clinical and Demographic characteristics of pediatric and adults (using CRF and DDCF),

(2) Fitness status of pediatric patients (using Child Health Questionnaire-Parent Form; CHQ-PF50),

(3) Standard of life of adult patients (using Life Quality Survey Form-36; [SF-36]),

(4) Effectiveness of ICT in pediatric and adult sufferers (using Case Report Form and ICT fulfillment Survey), and

(5) Agreement to ICT in pediatric and adult patients (using ICT fulfillment Survey).

The CHQ-PF50 (for children aged 5–18 years) measures HRQOL children as reported by the parent. The form includes 50 items providing 15 subtitles: common well-being , bodily functioning, role/social restrictions-emotional/behavioral, role/social limitations-physical, bodily pain/discomfort, performance, universal performance, emotional state, self-respect, common health state, health change, parent effect-emotional, parent effect-time, family activities, and family cohesion. In this trail, the items were recorded and the computed records were modified to a scale from 0 to 100. Higher records demonstrates superior health.

SF-36 is a self-administered generic questionnaire that measures two major subjective health concepts (i.e., bodily and mental well-being). The form contains 36 choice the best questions providing a profile of eight ideas:

(1) Physical working,

(2) Physical role restriction,

(3) Pain,

(4) Mental health,

(5) Emotional role restriction,

(6) Social working,

(7) Energy, and

(8) Common health realization.

SF-36 has also an item calculating health changes over the past year. The genuine and rationality of SF-36 are well recorded in all obtainable language versions. In this study, reactions to each of the SF-36 items were recorded and added according to a systematized achieving protocol and indicated as a record on a 0–100 scale for every 8 well-being concepts. Elevated scores specify superior self-recognized health.

The ICT fulfillment Survey used in the educate consisted of fulfillment-specific items calculating four domains:

(1) Perceived efficacy,

(2) Acceptance,

(3) Load of ICT, and

(4) Side effects.

Patient reactions to the items containing these domains were recorded, and the records were changed to a scale from 0 (worst fulfillment) to 100 (best fulfillment).

STATISTICAL ANALYSIS

Qualitative variables were indicated as number and %. Quantitative variables concerning health position of pediatric patients and agreement to ICT in pediatric and adult patients were described in the form of mean ± standard deviation (SD), median, and range. The other quantitative variables were expressed as mean ± SD. Statistical analysis was based on descriptive statistic procedures, and the comparison of means between two different groups was performed with the Student's *t*-test and Mann–Whitney U-test, for variables with usual and alter supply, respectively, GraphPad Prism version 5.01 or STATA/MP11 Package (StataCorp LP, TX, USA) for Windows (GraphPad Software, Inc., CA, USA). A $P < 0.05$ was considered statistically significant.

3. RESULTS AND DISCUSSIONS

DEMOGRAPHIC AND CLINICAL CHARACTERISTICS:

The demographic and clinical characteristics of the patients. The study population comprised 18 patients with BTM or SCA. All patients were receiving periodic blood transfusions. At the time of the study visit, the pediatric patients were being treated with DFX. The sufferers were receiving DFX treatment. The purpose of choosing their treatment were physician's advice, poor adherence to DFO, DFP, or DFX, and the failure of reimbursement system for DFO. The patients also had 1 or more concomitant diseases/conditions and were using other drugs for their diseases in addition to the iron chelators

Table_1: Demographic and clinical characteristics of deferasirox-treated patients

	Bt	**Sca**
No.of patients	8	10
Females	5	7
Males	3	3
Age		
Females	23.5±3.83	36.6±11.9
Males	26.6±6.3	36.6±10.7
Height		

Females	159.7±4.1	161.3±9.3
Males	168.2±2.8	172.1±8.7
Weight		
Female	55.8±9.8	57.9±11.0
Male	62±11.7	66.9±12.5
Education		
University	2	1
High school	1	1
Secondary school	3	2
Primary school	1	6
Illiterate	1	0
Reason for choosing dfx		
Physician recommendation	3	8
Poor adherence to dfo or dfp		
Difficulty with administration for dfo	2	2
Side effect (nausea/vomiting with dfp)	3	Na
Concomitant diseases/conditions		
Hepatitis b	1	Na
Hepatitis c	Na	1
Hepatomegaly	Na	1
Hypogonadism	1	Na
Cardiac diseases		
Heart failure	Na	1
Mitral insufficiency	Na	1
Arrhythmia	Na	2
Cirrhosis	Na	1
Cholecystectomy	Na	2
Osteoporosis	4	3
Type 1 dm	1	Na
Vision loss	Na	1
Concomitint drug use		

Alendronate	2	Na
Acetylsalicylic acid	Na	3
Benzathine phenoxymethyl pencillin	Na	1
Calcium	2	1
Calcitrol	Na	1
Cholecalciferol	2	Na
Cilazapril	Na	1
Dexamethasone	Na	1
Digoxin	Na	2
Diltiazem	Na	1
Epoetic beta	Na	1
Folic acid	6	9
Furosemide	Na	1
Hydroxyurea	Na	9
Levonorgestre	1	Na
Levothyroxine	Na	1
Medroxyprogesterone	2	Na
Metarpolol	Na	1
Nifidipine	Na	1
Paracetamol	Na	1
Risedronic acid	1	Na
Sodium bicarbonate	Na	2
Vitamin b12	1	1
Vitamine e	1	Na
Warfarin	Na	1
Zinc	5	Na



Graph.no:.1. No.Of Patients According To Gender



Graph.No: 2 Demographic And Clinical Characteristics

The SF-36 summary scores regarding the QOL in sufferers with BTM or SCA who accepted DFX. In particular, the average SF-36 scores in the DFX-treated sufferers with BTM ranged from 61.4±10.6for the physical functioning to 28.1±31.1the emotional role limitation. The results in the DFX-treated sufferers with SCA ranged from 51.3±10.9for the usual health perception to 51.4±29.1 the physical part restriction. When compared with the scores of the DFX-treated patients with BTM, the scores for physical functioning, physical role limitation, pain, social functioning, and vitality were notably less in the DFX-treated sufferers with SCA (P< 0.05). The differences between sufferers groups for the other scales were statistically not similar.

Table: 2 Health Questonnaire Form 50 Summary Scored In Dfx Treated In Patients with Btm and Sca

Scale	Btm	Sca	P value
Physical functioning	61.4±10.6	42.9±13.7	0.0002*
Physical role limitation	51.4±29.1	32.6±23.5	0.0010*
Pain	58.3±12.0	36.5±21.0	<0.0001*
Mental health	46.4±11.8	39.9±21.6	-
Emotional role limitation	28.1±31.1	27.0±13.0	-
Social functioning	57.9±11.5	38.1±19.8	0.0005*
Vitality	40.0±12.6	41.3±17.8	0.0207*
Health transition over the past year	48.9±14.2	49.0±20.6	-
General health perception	51.3±10.9	50.3±12.5	-



Graph.No:3 Health Questonnair Form 50 Summary Scored In Dfx Treated In Patients with Btm and Sca

The parameters for adult patients with BTM or SCA who received DFX. Especially, mean serum ferritin levels were significantly higher than the normal values (30.0-400.0 ng/mL) in the sufferers accepting DFX (BTM: 2198.0 ± 1941.0 ng/mL, SCA: 1544.0 ± 1470.0 ng/mL) (P< 0.05). In the DFX-treated sufferers with BTM, the values about platelet, EDW, basophil CRP, lymphocyte, direct bilirubin, neutrophil, AST, and total bilirubin were greater than the normal levels. The values about platelet, AST, EDW, monocyte, total bilirubin, direct bilirubin, and monocyte % were found to be greater than the normal ranges in the DFX-treated sufferers with SCA. The values about erythrocyte, hemoglobin and hematocrit, were lower in the DFX-treated sufferers with BTM or SCA. In the DFX-treated sufferers, the values for hemoglobin, hematocrit, platelet, erythrocyte, lymphocyte, lymphocyte percentage,

and ALT were less, and MCV and MCH were notably greater in the sufferers with SCA than the sufferers with BTM (P<0.05). The differences between sufferer groups for the other parameters were not notably not similar.

Table: 3 Haematological and Biochemical Parameters in Dfx Treated Patients with Sickle Cell Anemia and Beta Thalassemia

Parameter	BTM	SCA	P value
FERRITIN ng/ml	2198.0±194.0	1544.0±1470.0	-
Haemoglobin g/dl	9.5±1.5	7.9±1.2	0.002*
Hematocrit	28.5±4.6	23.2±3.7	0.001*
Platelets	742.8±286.0	470.4±298.2	0.014*
MPV	8.2±1.6	8.7±1.8	-
Platelet percentage	0.4±0.1	0.3v0.1	-
PDW	14.2±3.5	13.3±3.8	-
Erythrocyte	3.5±0.5	2.6±0.5	<0.0001*
MCV	83.1±4.2	89.9±9.1	0.0149*
MCH	27.3±1.9	31.1±4.7	0.0138*
MCHC	33.2±1.3	35.3±5.2	-
EDW	18.1±3.5	20.3±7.1	-
Eosinophil	0.5±0.4	0.3±0.2	-
Eosinophil percentage	2.6±2.2	2.3±1.5	-
Basophil	0.2±0.1	0.1±0.2	-
Basophil percentage	1.0±0.7	0.9±0.7	-
Neutrophil	7.2±3.4	7.0±4.0	-
Neutrophil percentage	46.2±11.8	52.6±16.1	-
Lymphocytes	6.8±2.8	3.6±1.7	0.0013*
Lymphocyte percentage	42.3±11.9	30.3±11.7	0.0208*
Monocyte	0.8±0.5	1.2±0.7	-
Monocyte percentage	6.6±0.4	9.8±5.7	-
Creatinine	0.6±0.4	1.00±1.1	-
Total bilirubin	2.5±1.5	2.9±2.8	-
Direct bilirubin	0.5±0.3	1.2±2.2	-
ALT	40.6±25.7	20.5±7.9	0.0039
AST	41.7v25.4	39.4±21.2	-
LDH	218.3±62.1		-
CRP	13.5±18.0	432.2±2529	-
		2.6±1.8	



Graph No 4: Hemotological And Biochemical Parameters In Dfx Treated Patients With Sickle Cell Anemia And Beta Thalassemia

EFFICACY OF IRON CHELATION TREATMENT

The ICT scores for sufferers with BTM or SCA who are accepting DFX are given in Table 4. In particular, the average scores in the DFX-treated sufferers with BTM ranged from 61.9±11.4 (n = 8) for the load of ICT to 52.0±12.9 (n = 10) for the perceived efficacy of ICT. Similarly, the scores in the DFX-treated patients with SCA ranged from 52.9±12.2 (n = 8) for the burden of ICT to 51.6±12.1 (n = 10) the perceived effectiveness of ICT. The differences between patient groups for the other scales were not statistically different.

Table 4: Iron Chelation Treatment Satisfaction Summery Score In Dfx Treated Patients With Btm And Sca

CONCEPT	BTM	SCA
Perceived effectiveness ICT	61.9±11.4	52.0±12.9
Acceptance ICT	68.5±8.90	62.5±13.9
Burden ICT	65.2±9.01	62.1±11.2
Side effect of ICT	52.9±12.2	51.6±12.1



Graph. No 5: iron chelation treatment satisfaction summery score in dfx treated patients with btm and sca

Table 5 Determine the proportional supply of SEs in the DFX-managed sufferers with BTM or SCA. No severe SEs necessitating discontinuation or interruption of treatment in the sufferers were documented, and no sufferers died during the trail

Table 5: proportional supply of ses in dfx treated patients with btm and sca.

PERCENTAGE	BTM	SCA
90-100	Hearing loss, blurred vision, increase in appetite, vomiting,flatulence, dyspepsia, decrease/increase in urine output, swelling in arms, legs and blackish discoloration of urine	Tinnitus or ringing in the ear, hearing loss, vision loss, increase in appetite, diarrhoea, constipation, flatulence, dyspepsia, decrease or increase output, shortness of breath, dizziness, faintness, cough, fever, skin rash, swelling in the arms /legs, blackish discoloration of urine and sleep disturbances
80-90	Vision loss,nausea, constipation, shortness of breath, cough, dizziness, faintness, skin rash, anxiety, sleep disturbances.	Blurred vision, decrease In appetite, vomiting, yellow skin and eyes, soar throat , muscle spasm, anxiety, hair loss
70-79	Tinnitus or ringing in the ears, decrease in appetite, diarrhoea, reddish brownish discoloration of urine	Headache and numbness or tingling in fingers and toes.
60-69	Yellow skin and eyes, myalgia, muscle spasm, fever, numbness or tingling in the fingers and toe and hair loss	Abdominal pain and myalgia.
50-59	Sore throat	Nausea, reddish/brownish discoloration of urine.
0-49	Abdominal pain, joint pain, headache	Joint pain.

The reason for this single-center observational trail was to assess QOL, clinical efficacy, and satisfaction in sufferers with BTM and SCA accepting DFX chelation treatment to contribute to their therapy and support process. The outcomes of the present trail indicate that the DFX-managed sufferers with BTM or SCA are not achieving their target hematological marker thresholds (mainly serum ferritin levels) despite long-term therapy for iron over burden. In addition, DFX chelation treatment appears to negative impact their HRQOL so that the sufferers fulfillment with ICT is usually poor.

Iron over burden is an important concern in sufferers with congenital, non transfusion-dependent thalassemia, SCA, fanconi anemia, hemolytic anemia, and sideroblastic anemia and acquired (e.g., aplastic anemia, red cell aplasia, neoplastic diseases, and bone marrow transplantation) anemias for whom regular transfusions are required. Non treated transfusional iron burden leads in harm to the liver, endocrine organs, and mostly to the heart. International regulations for treating of BTM and SCA concur on gaining a target serum ferritin of 1.000-2.500 µg/L and <1.000 µg/L, respectively. In patients with iron overload as a result of regular blood transfusions because of BTM and SCA, oral chelating agents (e.g. DFX and DFP) are preferred over DFO because of their ease of administration, lesser side effects and better compliance. Further, it takes months, sometimes yrs, to decrease serum ferritin ranges to a safe range. Combining chelators are sometimes used in high iron over burden. sufferers sometimes move from one chelator to alternate for a variety of causes, involving health status getting worsen due to iron over burden, SEs, and personal preference.

In fact, life expectancy is directly related to the standard of chelation therapy and poor compliance to therapy elevates the risk of difficulties and shortens existence. Serum ferritin calculation is useful for close and frequent sufferer examining to indicate alters in iron burden and determine current therapy needs. In the case of

elevated ferritin ranges, dosage may be reduced and sufferer preference in choice of chelator can be better presence. Further, all forms of therapy can be inconvenient, time-taking, and outcome in unpleasant SEs, all which could possibly impact physical and emotional functioning of sufferers. In our study, the DFX-managing sufferers with BTM or SCA were heavy iron over burden in agreement with old reports. The lack of therapy may explain the high ferritin ranges. The elevated serum ferritin ranges were also related with abnormalities in blood related and biochemical results. For instance, in the DFX-managed sufferers with BTM or SCA, the values about platelet, platelet %, MCH, EDW, basophil, neutrophil, lymphocyte, monocyte, monocyte percentage, total bilirubin, direct bilirubin, ALT, AST, and CRP were found to be greater than the normal ranges. further, the values about hemoglobin, hematocrit, and/or erythrocyte were less than the normal ranges in the sufferers. In the DFX-managed sufferers. Therefore, it indicates that in addition to their SEs on hematopoietic and liver functions, DFX is not to be efficient in decreasing serum ferritin range in sufferers with BTM or SCA.

HRQOL involves several aspects which involving domains associated to emotional, physical, mental, and social functioning and focuses on the impact health status has on QOL. Supporting healthy emotional functioning is important not only to psychological well-being but also to physical health as it may impact compliance to medical regimens. The significance of the CHQ-PF50 and SF-36 questionnaires and the outcomes of the particular scales on the actions that should be taken for sufferers with thalassemia or SCD have been documented. Further there is a little-published data on HRQOL in DFX-managed sufferers with BTM or SCA. Overall, our results regarding QOL and fulfillment with ICT show that the sufferers with BTM or SCA had less scores. For instance, the greatest CHQ-PF50 scores were observed to be for the family activities (86.0%) and the health transition (85.0%) in the DFX-managed sufferers with BTM or SCA, respectively. The highest SF-36 score was for the physical functioning (81%) in the DFX-treated patients with BTM. In the patients with SCA, the highest score was found to be for the general health perception (58.3%) in the DFX group.

It is also significant that the scores for usual health, physical functioning, role/social limitations-physical, parent impact-time, and family activities were less, and the scores for health transition were greater in the DFX-managed sufferers with SCA than the sufferers with BTM. Regarding fulfillment with ICT, when equated with the scores of the DFX-managed sufferers with BTM, the scores for perceived efficacy of ICT was less in the sufferers with SCA. It seems that poor agreement to DFX chelation treatment in these sufferers is mostly due to a complex combining of psychological/social/demographic factors, living with a chronic disease, concomitant conditions and drug use, and new challenges associated to improved life expectancy in the disorders. It is also possible that problems with therapy regimen and SEs appear to be usual causes of poor agreement to DFX chelation treatment in these sufferers. Overall, our results advises that the sufferers are not gaining their target serum ferritin thresholds despite chronic therapy for iron overload, ICT appears to negatively impact their HRQOL, and agreement to ICT is poor.

4. CONCLUSION

DFX showed significant scores for usual health, physical functioning, role/social limitations-physical, parent impact-time, and family activities less, and the scores for health transition were greater in the DFX-managed sufferers with SCA than the sufferers with BTM.

Regarding fulfillment with ICT, when equated with the scores of the DFX-managed sufferers with BTM, the scores for perceived efficacy of ICT was less in the sufferers with SCA. It seems that poor agreement to DFX chelation treatment in these sufferers is mostly due to a complex combining of psychological/social/demographic factors, living with a chronic disease, concomitant conditions and drug use, and new challenges associated to improved life expectancy in the disorders.

This study provides some evidence for differences in the limitations of quality of life and satisfaction among patients with BTM or SCA depending on the DFX chelation therapy. Overall, the patients involved in the study had not achieved target serum ferritin thresholds despite long-term treatment for iron overload with DFX chelation therapy. Observed compliance to DFX was generally poor, and treatment appeared to negatively impact the quality of life and satisfaction of the patients.

Our data also suggest that majority of the patients and/or their parents do not know about the importance of their medication. This trail stress on the significance of giving pediatric and adult patients with beta thalassemia or Sickle cell anemia with the best chelation therapy depending on their particular needs, in order to enlarge the HRQOL and reduce the existence of, hepatic, renal,

metabolic, endocrine, and cardiac comorbidities including side effects, leading to increased compliance, and thus resulting in optimal clinical benefit. Including, our outcomes highlight the necessity of participation of a multidisciplinary team in the controlling the sufferers with these diseases. Health care suppliers should have knowledge of the significance of observing iron burden with timely beginning of DFX chelation therapy, and ongoing adjustments to chelation transfusion methods in response to these measurements. Future studies needed to regulate the clinical variables and demographic most likely to be associated with successful ldecrease in iron overload as well as strategies) to lessen the hospitalizations, exceed the compliance to ICT of the patients, and reduce morbidity and mortality.

5. REFERENCES

1. Barcaccia, Barbara (4 September 2013). "Quality Of Life: Everyone Wants It, But What Is It?". Forbes/ Education. Retrieved 10 May 2016.

2. Bottomley, Andrew (2002). "The Cancer Patient and Quality of Life". The Oncologist. **7** (2): 120–125. doi:10.1634/theoncologist.7-2-120.

3. "What Are the Signs and Symptoms of Sickle Cell Disease?". National Heart, Lung, and Blood Institute. June 12, 2015. Archived from the original on 9 March 2016. Retrieved 8 March 2016.

4. "What Is Sickle Cell Disease?". National Heart, Lung, and Blood Institute. June 12, 2015. Archived from the original on 6 March 2016. Retrieved 8 March 2016.

5. "What Causes Sickle Cell Disease?". National Heart, Lung, and Blood Institute. June 12, 2015. Archived from the original on 24 March 2016. Retrieved 8 March 2016.

6. "How Is Sickle Cell Disease Diagnosed?". National Heart, Lung, and Blood Institute. June 12, 2015. Archived from the original on 9 March 2016. Retrieved 8 March 2016.

7. "Sickle-cell disease and other haemoglobin disorders Fact sheet N°308". January 2011. Archived from the original on 9 March 2016. Retrieved 8 March 2016.

8. "How Is Sickle Cell Disease Treated?". National Heart, Lung, and Blood Institute. June 12, 2015. Archived from the original on 9 March 2016. Retrieved 8 March 2016.

9. GBD 2015 Disease and Injury Incidence and Prevalence, Collaborators. (8 October 2016). "Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015". Lancet. **388** (10053): 1545–1602.

10. GBD 2015 Mortality and Causes of Death, Collaborators. (8 October 2016). "Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015". Lancet. **388** (10053):

11. "Learning About Sickle Cell Disease". National Human Genome Research Institute. May 9, 2016. Archived from the original on January 4, 2017. Retrieved January 23, 2017.

12. Global Burden of Disease Study 2013, Collaborators (22 August 2015). "Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013".

13. Rees, DC; Williams, TN; Gladwin, MT (11 December 2010). "Sickle-cell disease". Lancet. **376** (9757):